retatrutide clinical trials brazil ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Retatrutid Clinical Trials

8 Observational studies indicate that women with GDM who follow a DASH or Mediterranean diet postpartum have a lower incidence of hypertension and T2D

GLP1-S from Adapt Peptides is provided strictly for laboratory research use and is not FDA-approved for human or veterinary use

In these cases, the weight-related health risk is immediate and serious, the drugs cardiovascular and metabolic benefits are well-evidenced, and the risk-benefit calculation clearly favours pharmacological intervention

Dietary impact on fasting and stimulated GLP-1 secretion in different metabolic conditions a narrative review

10.1016/0968-000490148-x Trends Biochem Sci

Nat Rev Neurol 15:459472 Geronzi U, Lotti F, Grosso S (2018) Oxidative stress in epilepsy